REDUCE DOWNSTREAM COSTS WITH DIAGNOSTIC AND PROGNOSTIC TESTING

At Mayo Clinic, we know the importance of laboratory testing in a patient’s episode of care. Our unique combination of specialized laboratories and cardiology patient-care clinics allows us to:

- **Reduce downstream costs** with care-driven testing approaches that produce definitive diagnoses.
- **Identify at-risk patients** who require earlier intervention or increased surveillance.
- **Evaluate and treat patients** using the most advanced techniques and technologies.
- **Develop and validate state-of-the-art tests** in a clinical setting.

**MAYO CLINIC CARDIOLOGY BY THE NUMBERS**

- **2** Mayo Clinic’s rank in the 2015–16 U.S. News and World Report list of top cardiology and heart surgery hospitals
- **200+** Cardiologists on staff
- **4,000+** Patients treated for hypertrophic cardiomyopathy (HCM)
- **1,000+** Unrelated patients receiving genetic testing for inherited HCM
- **160+** Cardiology-specific tests in our comprehensive test menu
- **50+** Research centers, programs, and core laboratories
- **38** Live conferences to educate medical professionals in 2015
- **77** Cardiology related clinical trials currently open for enrollment
- **700+** Research articles published in 2013
- **TESTING CATEGORIES**
  - BIOMARKER PANELS
  - NEXT GENERATION SEQUENCING PANELS
  - LIPIDS AND LIPOPROTEINS
  - PHARMACOGENOMICS
  - HEART FAILURE
  - INFLAMMATION
  - PROTEOMICS
  - ANATOMIC PATHOLOGY
TARGETED GENETIC TESTING PANELS OFFER HIGH CLINICAL UTILITY

Next-generation sequencing (NGS) is an accurate, cost-effective method of identifying inherited variants across numerous genes known to be associated with cardiac disorders.

Our targeted cardiovascular NGS panels include evaluations for:

- **HYPERTROPHIC CARDIOMYOPATHY** 26 GENES
- **DILATED CARDIOMYOPATHY** 30 GENES
- **COMPREHENSIVE CARDIOMYOPATHY** 55 GENES
- **ARRYTHMOGENIC CARDIOMYOPATHY** 9 GENES
- **MARFAN SYNDROME & RELATED DISORDERS** 13 GENES
- **NOONAN SYNDROME & RELATED DISORDERS** 11 GENES
- **LONG QT SYNDROME** 13 GENES
- **BRUGADA SYNDROME** 9 GENES

CONSULT WITH MAYO CLINIC GENETIC COUNSELORS ABOUT TESTING OPTIONS

Genetic counselors bring real value to proper test utilization by making sure the most appropriate test has been ordered. On average, Mayo Clinic genetic counselors modify 8% of all reviewed genetic test orders1, reducing health care costs and benefiting patient care.

Mayo Clinic genetic counselors are available to:

- Support the ordering process
- Provide additional information about testing options
- Offer results interpretation
- Assist with case review and coordination

NOVEL BIOMARKERS FOR CARDIOVASCULAR DISEASE

Standard cardiovascular risk factors only predict about 65% of individuals who will experience a cardiovascular event. As a result, Mayo Clinic physicians are continually investigating novel biomarkers of cardiovascular disease to find those with proven clinical utility.

Appropriate ordering scenarios for our novel biomarker testing, interpreted by cardiovascular experts, may include:

- Determining risk for adverse cardiovascular events (Plasma Ceramides).
- Improving prognostic discrimination among heart failure patients (Soluble ST2).
- Predicting CHD risk associated with atherosclerotic plaques (Lp-PLA₂ Activity).

24/7 LAB SUPPORT AND BILLING SOLUTIONS

- We encourage clients to call and speak with one of our laboratory directors or genetic counselors, free of charge, should they have questions.
- Mayo Laboratory Inquiry answers all calls personally, 24 hours a day, every day. We resolve more than 99% of inquiries with a single phone call.
- Dedicated support teams located in your region offer support on any laboratory matter.
- Our service and logistics experts guide you through reimbursement or other billing-related questions, including third-party billing and prior authorization.

Telephone 855-516-8404
Email rstmmicardiology@mayo.edu

---

TAP INTO THE EXPERTISE OF MAYO CLINIC

The Cardiovascular Laboratory Medicine Group within Mayo Clinic works to accommodate the growing demand for development, validation, and use of analytes to predict risk for both primary and secondary prevention.

Focused on acute-care cardiology, risk stratification, and genomics, the group integrates laboratory cardiology with its colleagues in cardiology, pediatric cardiology, genetics, cardio-thoracic and vascular surgery—as well as cerebrovascular specialists in neurology.

FOR MORE INFORMATION ABOUT CARDIOVASCULAR TESTING, VISIT MayoMedicalLabs.com/cardiology